Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Edwards recently made two acquisitions totaling $1.2 billion in the heart device sector, while also reporting a slowdown in its core business. Owens & Minor agreed to a $1.36 billion takeover of Rotech to expand its home medical equipment offerings. Inspire Medical's COO is leaving to become CEO of a cardiology-focused medical device company. CDRH director Shuren is stepping down after 15 years, with Michelle Tarver serving as acting director. Boston Scientific anticipates strong growth for Farapulse after a successful launch, reflecting the ongoing trends and changes in the medtech industry.Tenet's earnings beat expectations, prompting an increase in full-year guidance. Hill Democrats are working to codify the Chevron doctrine, with a bill introduced by Warren and other lawmakers. Adventist Healthcare has appointed a new CEO, while PBMs are facing scrutiny from lawmakers. Molina's Medicaid growth offset redetermination pressures in Q2. AI is being used to transform unstructured patient data into structured reports, as well as in clinical trial protocol development. Overall, the healthcare industry is experiencing shifts and reforms as various players navigate challenges and opportunities.Sanofi's immunology pipeline shows promise as sales of Dupixent rise, Viking plans to accelerate its obesity drug into late-stage testing, and Kamala Harris takes a stance on key pharma issues. Warren and Democratic lawmakers introduce a bill to revive the Chevron doctrine, while Pfizer's hemophilia gene therapy meets late-stage study goals. The pharma industry is racing to develop GLP-1 drugs for obesity treatment, with the market expected to surpass $100 billion. The newsletter covers a range of topics in biotech and pharma, including clinical trials, drug pricing, gene therapy, and more. Biopharma Dive provides in-depth journalism and insight into the most impactful news and trends in the industry.AI-designed drugs have shown promising results in phase 1 testing, with an 80%-90% success rate compared to traditionally developed drugs. However, in phase 2, the success rate falls closer to the industry average of 40%. The sample size of phase 2 candidates was small, with just 10 drugs included, as few AI molecules have advanced that far. Despite this, pharma companies and biotech investors are still backing the AI dream, with companies like Mubadala Capital investing in life sciences companies leveraging AI platforms for drug R&D. The future success of AI-designed drugs in clinical trials remains to be seen as more AI molecules progress through the pipeline. Meagan Parrish discusses where Alabdallah of Mubadala Capital sees promise in biotech and why he continues to support AI platform companies for drug development. Additionally, the newsletter covers Kamala Harris' stance on key pharma issues, tips for a successful therapeutic launch, and resources on testing cognition in Alzheimer's disease clinical trials and using data to upgrade drug commercialization strategies.